Evidence map›Paper›PMID 36962660›Full record

ArticlePLOS global public health2022

Evaluation of the Nigeria national HIV rapid testing algorithm.

Nnaemeka C Iriemenam, Augustine Mpamugo, Akudo Ikpeazu, Olumide O Okunoye, Edewede Onokevbagbe, Orji O Bassey, Jelpe Tapdiyel, Matthias A Alagi, Chidozie Meribe, Mukhtar L Ahmed and 22 more

Full text read
In one paragraph

Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Nnaemeka C IriemenamDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0003-2187-8894
Augustine MpamugoCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0003-1803-4690
Akudo IkpeazuFederal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.
Olumide O OkunoyeDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0003-0832-5240
Edewede OnokevbagbeCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
Orji O BasseyDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
Jelpe TapdiyelDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0002-4756-6509
Matthias A AlagiDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0002-6188-3527
Chidozie MeribeDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
Mukhtar L AhmedDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
Gabriel IkwulonoFederal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.
Rose AguoluNational Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0002-5772-0063
Gregory AsheforNational Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria.
Charles NzeluFederal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.
Akipu EhocheCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
Babatunde EzraCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
Christine ObiohaCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0002-7043-4651
Ibrahim Baffa SuleCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0001-6997-0943
Oluwasanmi AdedokunCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0002-4678-9735
Nwando MbaNational Reference Laboratory, Nigeria Centers for Disease Control, Gaduwa, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0003-2998-2354
Chikwe IhekweazuNational Reference Laboratory, Nigeria Centers for Disease Control, Gaduwa, Federal Capital Territory, Nigeria.
Manhattan CharuratInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-1719-2796
Brianna LindsayCenter for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0001-6116-3864
Kristen A StaffordInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0001-5620-6436
Dalhatu IbrahimDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0002-3287-5173
Mahesh SwaminathanDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
Ernest L YufenyuyInternational Laboratory Branch, Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Bharat S ParekhInternational Laboratory Branch, Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0002-1088-4263
Sylvia AdebajoCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.ORCID https://orcid.org/0000-0002-5933-8044
Alash'le AbimikuInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0003-2213-0204
McPaul I OkoyeDivision of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
Evaluation Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human Immunodeficiency Virus (HIV) diagnosis remains the gateway to HIV care and treatment. However, due to changes in HIV prevalence and testing coverage across different geopolitical zones, it is crucial to evaluate the national HIV testing algorithm as false positivity due to low prevalence could be detrimental to both the client and the service delivery. Therefore, we evaluated the performance of the national HIV rapid testing algorithm using specimens collected from multiple HIV testing services (HTS) sites and compared the results from different HIV prevalence levels across the six geopolitical zones of Nigeria. The evaluation employed a dual approach, retrospective, and prospective. The retrospective evaluation focused on a desktop review of program data (n = 492,880) collated from patients attending routine HTS from six geopolitical zones of Nigeria between January 2017 and December 2019. The prospective component utilized samples (n = 2,895) collected from the field at the HTS and tested using the current national serial HIV rapid testing algorithm. These samples were transported to the National Reference Laboratory (NRL), Abuja, and were re-tested using the national HIV rapid testing algorithm and HIV-1/2 supplementary assays (Geenius to confirm positives and resolve discordance and multiplex assay). The retrospective component of the study revealed that the overall proportion of HIV positives, based on the selected areas, was 5.7% (28,319/492,880) within the study period, and the discordant rate between tests 1 and 2 was 1.1%. The prospective component of the study indicated no significant differences between the test performed at the field using the national HIV rapid testing algorithm and the re-testing performed at the NRL. The comparison between the test performed at the field using the national HIV rapid testing algorithm and Geenius HIV-1/2 supplementary assay showed an agreement rate of 95.2%, while that of the NRL was 99.3%. In addition, the comparison of the field results with HIV multiplex assay indicated a sensitivity of 96.6%, the specificity of 98.2%, PPV of 97.0%, and Kappa Statistic of 0.95, and that of the NRL with HIV multiplex assay was 99.2%, 99.4%, 99.0%, and 0.99, respectively. Results show that the Nigeria national serial HIV rapid testing algorithm performed very well across the target settings. However, the algorithm's performance in the field was lower than the performance outcomes under a controlled environment in the NRL. There is a need to target testers in the field for routine continuous quality improvement implementation, including refresher trainings as necessary.

Identifiers

PMID36962660
PMCPMC10021713

What OpenQuestion holds

Textfull text, public
LicenceCC0
measurements read149
identifiers read9
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.